NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free PSNL Stock Alerts $1.25 -0.05 (-3.85%) (As of 12:58 PM ET) Add Compare Share Share Today's Range$1.18▼$1.2850-Day Range$1.20▼$1.7552-Week Range$0.89▼$2.60Volume111,015 shsAverage Volume373,995 shsMarket Capitalization$63.13 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Personalis alerts: Email Address Personalis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside340.0% Upside$5.50 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1,702 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.58) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector173rd out of 907 stocksMedical Laboratories Industry7th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.62% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently decreased by 0.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Personalis this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,702.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.58) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Personalis Stock (NASDAQ:PSNL)Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More PSNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSNL Stock News HeadlinesApril 24, 2024 | businesswire.comPersonalis to Announce First Quarter 2024 Financial ResultsApril 2, 2024 | investing.comCathie Wood's ARK makes major moves in Tesla stock, sells RobinhoodApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 29, 2024 | investing.comCathie Wood's ARK buys over $14M in Tesla stock, sells Coinbase in latest tradesMarch 28, 2024 | businesswire.comPersonalis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | businesswire.comData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 26, 2024 | finance.yahoo.comPersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response MonitoringMarch 19, 2024 | businesswire.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 16, 2024 | finance.yahoo.comPSNL Apr 2024 2.500 putMarch 6, 2024 | finance.yahoo.comPSNL Apr 2024 7.500 callMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Personalis’s Strategic Advances and Financial Health Signal Promising Growth in 2024March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth ProspectsMarch 1, 2024 | seekingalpha.comPersonalis, Inc. (PSNL) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | uk.finance.yahoo.comPersonalis, Inc. (PSNL)February 29, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | benzinga.comPersonalis: Q4 Earnings InsightsFebruary 28, 2024 | finance.yahoo.comPersonalis Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comWhat Wall Street expects from Personalis's earningsFebruary 14, 2024 | finance.yahoo.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | businesswire.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsJanuary 31, 2024 | finance.yahoo.comPersonalis to Participate at Upcoming Investor ConferencesJanuary 30, 2024 | markets.businessinsider.comPersonalis, ClearNote Health Join Hands To Advance Epigenomic TechnologyJanuary 30, 2024 | finance.yahoo.comPersonalis and ClearNote Health Announce Partnership to Advance Epigenomic TechnologyJanuary 22, 2024 | finance.yahoo.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 16, 2024 | finance.yahoo.comPersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling AssayJanuary 7, 2024 | uk.investing.comPersonalis reports 18% Q4 revenue growth, eyes 2026 runwaySee More Headlines Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees223Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.50 Low Stock Price Target$3.50 Potential Upside/Downside+340.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-147.38% Pretax Margin-147.27% Return on Equity-61.42% Return on Assets-41.05% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio2.88 Sales & Book Value Annual Sales$73.48 million Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.47Miscellaneous Outstanding Shares50,504,000Free Float48,433,000Market Cap$63.14 million OptionableOptionable Beta1.95 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Christopher M. Hall (Age 55)President, CEO & Director Comp: $963.75kMr. Aaron L. Tachibana (Age 63)CFO & COO Comp: $811kMr. Stephen M. Moore J.D. (Age 52)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $597.98kDr. Richard Chen M.D. (Age 53)M.S., Executive VP of R&D and Chief Medical Officer Comp: $800.6kDr. Russ B. Altman M.D.Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Euan A. Ashley DPHIL (Age 53)FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Michael J FitzpatrickVice President of Worldwide SalesDr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Laboratory OperationsMr. Stephane Mouradian Ph.D.Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZAkuminNASDAQ:AKUMQExagenNASDAQ:XGNDermTechNASDAQ:DMTKBiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 106,051 shares on 4/19/2024Ownership: 1.936%State of Michigan Retirement SystemBought 50,000 shares on 4/18/2024Ownership: 0.978%Quadrature Capital LtdBought 73,001 shares on 3/25/2024Ownership: 0.145%Bruce & Co. Inc.Bought 150,000 shares on 2/12/2024Ownership: 0.612%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PSNL Stock Analysis - Frequently Asked Questions Should I buy or sell Personalis stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks. What is Personalis' stock price target for 2024? 2 equities research analysts have issued 1 year price objectives for Personalis' stock. Their PSNL share price targets range from $3.50 to $7.50. On average, they predict the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 340.0% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts. How have PSNL shares performed in 2024? Personalis' stock was trading at $2.10 on January 1st, 2024. Since then, PSNL shares have decreased by 40.5% and is now trading at $1.25. View the best growth stocks for 2024 here. When is Personalis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PSNL earnings forecast. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The company earned $19.68 million during the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 61.42%. What ETF holds Personalis' stock? ARK Genomic Revolution ETF holds 6,189,966 shares of PSNL stock, representing 0.56% of its portfolio. What guidance has Personalis issued on next quarter's earnings? Personalis updated its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Personalis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.94%) and State of Michigan Retirement System (0.98%). Insiders that own company stock include Aaron Tachibana, Christopher M Hall, John Stephen West, Lightspeed Venture Partners Se, Richard Chen and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSNL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.